+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID05962541

Using MRI-based VI-RADS and Photodynamic TURBT to Avoid Repeat Bladder Tumor Surgery in Non-Muscle Invasive Bladder Cancer A Phase IV Randomized Study Comparing This Approach to Standard White Light TURBT and Repeat Surgery

Led by University of Roma La Sapienza · Updated on 2025-12-31

327

Participants Needed

1

Research Sites

156 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new approach for treating non-muscle-invasive bladder cancers NMIBCs, focusing on avoiding unnecessary second surgeries called repeat transurethral resections of bladder tumors Re-TURBT. This phase IV, open-label, randomized controlled trial compares a modern imaging-guided surgery using photodynamic diagnosis PDD-TURBT after MRI staging with the current standard of care involving white light cystoscopy and mandatory Re-TURBT. The study aims to reduce overtreatment, improve patient quality of life, and lower healthcare costs while ensuring cancer control. Participants will be randomized into two groups one receiving PDD-TURBT without a second surgery, and the other following standard care with white light TURBT followed by Re-TURBT within 2 to 6 weeks. The PDD-TURBT uses a photosensitizer drug hexaminolevulinate inserted into the bladder and special blue light equipment to better detect tumors during surgery. The trial includes a total of 112 participants per arm, with all receiving initial MRI-based VI-RADS scoring to exclude muscle-invasive disease. Throughout the study, participants will undergo regular follow-ups including cystoscopy and imaging to monitor for early bladder cancer recurrence within 4.5 months and later outcomes over three years. Researchers will assess recurrence rates, progression to muscle-invasive cancer, patients health-related quality of life, and cost effectiveness. The study is designed to provide evidence for potentially updating treatment guidelines and reducing the burden of repeated surgeries for bladder cancer patients.

CONDITIONS

Brief Title

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Research Team

F

Francesco Del Giudice, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here